MAIA activates new site for THIO-101 Phase II trial
The trial is studying ateganosine followed by cemiplimab in NSCLC patients resistant to checkpoint inhibitors and chemotherapy.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance